Scarica l'app Stockscreener
22.74
4.17%
0.91
Dopo l'orario di chiusura:
22.74
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ARQT Giù?
Forum
Previsione
Precedente Chiudi:
$21.83
Aprire:
$22.03
Volume 24 ore:
808.30K
Relative Volume:
0.55
Capitalizzazione di mercato:
$2.82B
Reddito:
$376.07M
Utile/perdita netta:
$-16.14M
Rapporto P/E:
-162.54
EPS:
-0.1399
Flusso di cassa netto:
$-16.31M
1 W Prestazione:
+2.25%
1M Prestazione:
-15.81%
6M Prestazione:
+35.92%
1 anno Prestazione:
+32.90%
Intervallo 1D:
$21.95
$23.00
Intervallo di 1 settimana:
$21.57
$23.46
Portata 52W:
$11.86
$31.77
Arcutis Biotherapeutics Inc Stock (ARQT) Company Profile
Nome
Arcutis Biotherapeutics Inc
Settore
Industria
Telefono
805-418-5006
Indirizzo
3027 TOWNSGATE ROAD, WESTLAKE VILLAGE, CA
Compare ARQT vs VRTX, REGN, ALNY, ARGX, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ARQT
Arcutis Biotherapeutics Inc
|
22.74 | 2.71B | 376.07M | -16.14M | -16.31M | -0.1399 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Arcutis Biotherapeutics Inc Stock (ARQT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-25 | Iniziato | Goldman | Neutral |
| 2024-12-30 | Iniziato | H.C. Wainwright | Buy |
| 2024-08-28 | Iniziato | Jefferies | Buy |
| 2024-01-03 | Aggiornamento | Mizuho | Neutral → Buy |
| 2023-10-26 | Downgrade | Mizuho | Buy → Neutral |
| 2023-10-13 | Downgrade | Goldman | Buy → Neutral |
| 2022-09-07 | Iniziato | Needham | Buy |
| 2022-03-17 | Iniziato | Goldman | Buy |
| 2021-06-30 | Iniziato | Mizuho | Buy |
| 2021-05-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-09 | Aggiornamento | Goldman | Neutral → Buy |
| 2020-10-08 | Iniziato | Truist | Buy |
| 2020-02-25 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-02-25 | Iniziato | Cowen | Outperform |
| 2020-02-25 | Iniziato | Goldman | Neutral |
| 2020-02-25 | Iniziato | Guggenheim | Buy |
Mostra tutto
Arcutis Biotherapeutics Inc Borsa (ARQT) Ultime notizie
Arcutis (ARQT) announces long-term phase 3 data for ZORYVE cream in children - MSN
Understanding the Setup: (ARQT) and Scalable Risk - Stock Traders Daily
Arcutis Biotherapeutics (ARQT) Valuation Check After New Pediatric ZORYVE Phase 3 Extension Data - Yahoo Finance
Arcutis (ARQT) Announces Long-Term Phase 3 Data for ZORYVE Cream in Children - Insider Monkey
Arcutis to Present New Clinical Data in a Late-Breaking Podium Presentation and Scientific Posters at the 2026 American Academy of Dermatology Annual Meeting - Bitget
Arcutis Biotherapeutics (ARQT) Unveils New Trial Data at Dermato - GuruFocus
New eczema treatment data in infants and kids set for 2026 AAD - Stock Titan
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Arcutis Biotherapeutics, Inc. (ARQT) Eyes Pediatric Expansion for ZORYVE Cream - MSN
Fundamentals Check: Can Arcutis Biotherapeutics Inc stock outperform in a bear market2026 PostEarnings & Risk Managed Trade Strategies - baoquankhu1.vn
Are Medical Stocks Lagging Arcutis Biotherapeutics (ARQT) This Year? - MSN
Ally Bridge Group NY LLC Invests $4.40 Million in Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Arcutis Biotherapeutics, Inc. $ARQT Stock Holdings Lessened by Suvretta Capital Management LLC - MarketBeat
Stock Recap: Can Arcutis Biotherapeutics Inc sustain earnings growth2026 WrapUp & Expert-Curated Trade Recommendations - baoquankhu1.vn
The Technical Signals Behind (ARQT) That Institutions Follow - Stock Traders Daily
Arcutis reports long-term data on eczema cream for young children - Investing.com Canada
Arcutis reports long-term data on eczema cream for young children By Investing.com - Investing.com South Africa
Arcutis Biotherapeutics (ARQT) Reports Positive Findings from Zo - GuruFocus
Jefferies Remains a Buy on Arcutis Biotherapeutics (ARQT) - The Globe and Mail
Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data with ZORYVE® (roflumilast) Cream 0.05% for Treatment of Mild-to-Moderate Atopic Dermatitis in Children Ages 2-5 in Pediatric Dermatology - The Manila Times
Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data with ZORYVE (roflumilast) Cream 0.05% for Treatment of Mild-to-Moderate Atopic Dermatitis in Children Ages 2-5 in Pediatric Dermatology - Bitget
Year-long eczema study: Arcutis cream eased symptoms in young kids - Stock Titan
ARQT Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Arcutis Launches First-in-Human ARQ-234 Trial, Expanding Its Atopic Dermatitis Pipeline - TipRanks
Arcutis (ARQT) Q4 2025 Earnings Call Transcript - AOL.com
Guggenheim Raises Its Price Target on Arcutis Biotherapeutics, Inc. (ARQT) to $35 and Maintains a Buy Rating - Yahoo Finance
GW&K Investment Management LLC Sells 206,391 Shares of Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
10 Fastest Growing NASDAQ Stocks to Buy - Insider Monkey
Arcutis Announces Promotion of Mas Matsuda to Executive Vice President and Chief Legal Officer to Support Next Phase of Growth - Sahm
Arcutis Promotes Mas Matsuda to Executive Vice President, Chief Legal Officer - Contract Pharma
Mas Matsuda Promoted to Executive Vice President and Chief Legal Officer at Arcutis Biotherapeutics - geneonline.com
Arcutis Biotherapeutics (ARQT) Elevates Legal Leader to Executiv - GuruFocus
Arcutis Biotherapeutics Promotes Mas Matsuda to Executive Vice President and Chief Legal Officer - Quiver Quantitative
ARQT SEC FilingsArcutis Biotherapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Arcutis (ARQT) Earnings Call Signals Scaled Growth - TipRanks
Insider Sell Alert: Howard Welgus Sells 10,000 Shares of Arcutis Biotherapeutics Inc (ARQT) - GuruFocus
Arcutis Biotherapeutics Director Sells Shares - TradingView
Arcutis (ARQT) director sells 39,272 shares under 10b5-1 plan - Stock Titan
Vanguard Group Inc. Buys 96,991 Shares of Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Arcutis Biotherapeutics Spotlights ZORYVE Surge, 2025 Revenue Beat and Key FDA Milestones at TD Cowen - MarketBeat
Arcutis Biotherapeutics (NASDAQ:ARQT) Insider Sells 3,687 Shares - MarketBeat
Masaru Matsuda Sells 3,325 Shares of Arcutis Biotherapeutics (NASDAQ:ARQT) Stock - MarketBeat
Masaru Matsuda Sells 8,733 Shares of Arcutis Biotherapeutics (NASDAQ:ARQT) Stock - MarketBeat
Patrick Burnett Sells 6,287 Shares of Arcutis Biotherapeutics (NASDAQ:ARQT) Stock - MarketBeat
Insider Selling: Arcutis Biotherapeutics (NASDAQ:ARQT) Insider Sells 37,349 Shares of Stock - MarketBeat
Arcutis (ARQT) officer sells 3,687 shares and receives major equity grants - Stock Titan
Arcutis (ARQT) director Watanabe sells shares and receives large option, RSU awards - Stock Titan
Arcutis enrolls first patient in ARQ-234 atopic dermatitis trial By Investing.com - Investing.com Australia
A Look At Arcutis Biotherapeutics (ARQT) Valuation After New Trial Launch And Upgraded Revenue Outlook - simplywall.st
Arcutis Begins Enrolling Phase 1a/1b Study Evaluating ARQ-234, a CD200R Agonist, in Healthy Volunteers and Adults With Atopic Dermatitis - Bitget
Arcutis Biotherapeutics Begins Enrollment for Phase 1a/1b Atopic Dermatitis Study - marketscreener.com
Arcutis Biotherapeutics Inc Azioni (ARQT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):